Delenex completes its management team

Thomas Jung becomes chief medical officer

Swiss firm Delenex Therapeutics has appointed Thomas Jung as its chief medical officer.

A board certified dermatologist, Jung has led research work in immunology at the Novartis Research Institute in Vienna, Austria, then spent nine years at Novartis in Basel, Switzerland.

In January 2008 he took leadership of the Ilaris development team, until its first marketing approval in 2009. Since then, he was part of the senior leadership team at the Novartis Institute for Biomedical Research (NIBR), most recently as EU Head of Translational Medicine.

Delenex was created in September 2009 as a spin-off from ESBATech (now part of Alcon, the eye care division of Novartis), and is the exclusive licensee for any non-ophthalmic uses of ESBATech's products and IPR pre-dating the spin-off.

Eric de La Fortelle, ceo of Delenex, said: ‘With the arrival of an experienced clinician, initially trained in dermatology but with significant clinical development experience in several other therapeutic areas, notably autoimmunity, gastroenterology, respiratory, neurosciences and musculoskeletal disorders, Delenex is able to do full justice to its powerful discovery platform, and implement the best clinical programmes to bring its major new compounds to clinical proof of concept.’

You may also like

Distribution

Yusen Logistics Group completes acquisition of Walden Health, strengthening global healthcare logistics capabilities

Yusen Logistics Global Management is pleased to announce that Yusen Logistics (Europe) BV, an overseas subsidiary of Yusen Logistics Group, has completed the acquisition of the Walden Group subsidiaries Movianto, Eurotranspharma, Transpharma International and Walden Digital
Regulatory

Grifols receives US FDA approval for new fibrinogen concentrate: FESILTY (fibrinogen, human-chmt)

The fibrinogen concentrate complements Grifols’ bleeding management portfolio, expanding therapeutic options for patients
Regulatory

Hansa Biopharma submits BLA to FDA for Imlifidase in desensitisation for kidney transplantation

Imlifidase is an enzyme that rapidly and efficiently cleaves all types of immunoglobulin G (IgG) antibodies both intra- and extra-vascularly to inhibit IgG-mediated immune response
Finance

Symbiosis begins commercial manufacturing at new FDA-inspected facility

Symbiosis Pharmaceutical Services (Symbiosis), a leading sterile fill-finish contract manufacturing organisation (CMO), has manufactured its first 10,000-vial batch at the company’s new facility in Stirling, UK
Manufacturing

The story of an East-West German company | 150 years of Romaco Kilian

Kilian’s story tells of the rise, fall and resurgence of a Berlin company steeped in tradition, which is now based in Cologne. It is the story of the entrepreneur Fritz Kilian, who turned a small locksmith’s workshop in Berlin into a successful company that is still a leading manufacturer of tablet presses today. It is the story of a visionary whose legacy has endured the test of time and continues to this day
Manufacturing

Dual stage degasser vacuum pump from Biotech Fluidics

Biotech Fluidics has introduced a durable dual stage moulded vacuum pump designed to improve your fluidic degassing experience
Manufacturing

Thermo Fisher Scientific Expands Gibco Bacto portfolio

Its next-generation, chemically defined media will boost E. coli biomanufacturing productivity, helping innovators scale plasmid DNA and protein production with confidence
Subscribe now